Skip to content

Released Feb 27, 2018, after the close

10-K filed Feb 27, 2018, 58 days after period end · 0001232524-18-000018

Q4 2017 · 10-K
Revenue$436.40M+10.0% vs Q4 2016+6.0% vs Q3 2017
Net Income$232.21M+99.0% vs Q4 2016+265.5% vs Q3 2017
EPS Diluted$3.79+98.4% vs Q4 2016+268.0% vs Q3 2017
Gross Profit$404,847,000+12.8%
Operating Incomederived$141,205,000−14.7%
Operating Cash Flowderived$204,559,000+13.2%
Free Cash Flowderived$195,681,000+9.1%
Margins · derived
Gross margin92.8%+2.3 pt vs Q4 2016
Operating margin32.4%−9.4 pt vs Q4 2016
Net margin53.2%+23.8 pt vs Q4 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2017Q4 2016Q4 2015Q4 2014
Revenue$436.40M$396.62M$340.88M$328.14M
Net Income$232.21M$116.69M$82.76M$81.61M
EPS Diluted$3.79$1.91$1.32$1.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR